![]() |
市場調查報告書
商品編碼
1541627
人工授精市場報告按類型(子宮內、子宮頸內、陰道內、輸卵管內)、來源類型(AIH-丈夫、AID-捐贈者)、最終用途(醫院和診所、生育中心等)和地區2024-2032Artificial Insemination Market Report by Type (Intrauterine, Intracervical, Intravaginal, Intratubal), Source Type (AIH-Husband, AID-Donor), End Use (Hospitals and Clinics, Fertility Centers, and Others), and Region 2024-2032 |
IMARC Group年,全球人工授精市場規模達21億美元。不斷上升的不孕率、快速的生活方式改變以及不斷上升的醫療狀況是推動市場發展的一些關鍵因素。
人工授精是一種受精過程,涉及透過醫療程序將精子直接放入女性生殖系統。它通常涉及使用新鮮或冷凍精子,並且可以透過多種方式完成,包括子宮頸內、子宮內或陰道內方法。人工授精的組成部分包括精液採集、精液處理和精液放置。人工授精可以增加受孕機會,降低性傳染感染 (STI) 的風險,並且可以在男性不孕的情況下使用捐贈者的精子。此外,與體外受精(IVF)相比,人工授精具有微創性(MI)且具成本效益。目前,該程序有兩種主要類型,包括同源和異源。同源授精涉及使用男性伴侶的精子使女性伴侶的卵子受精,而異源授精涉及使用捐贈者的精子使女性伴侶的卵子受精。
不斷增加的不孕率和對輔助生殖技術(ART)的需求是推動市場成長的一些關鍵因素。生活方式的快速改變和多囊性卵巢症候群(PCOS)和子宮內膜異位症等疾病的盛行率不斷上升,增加了對人工授精手術的需求,進一步加速了市場成長。新興經濟體對人工授精的接受度和可近性的不斷提高進一步支持了這一點。此外,各種技術進步,例如精子和卵子選擇、冷凍保存和植入前基因檢測改進技術的發展,正在推動市場成長。除此之外,捐贈精子和捐贈卵子的可用性、同性婚姻和 LGBT 育兒的日益普及以及醫療基礎設施的改善預計將推動市場成長。此外,有利法規的存在、對不孕症和人工授精的認知和教育活動不斷增強,以及對個人化和客製化人工授精程序的需求不斷增加,都推動了市場的成長。其他因素,例如提供人工授精服務的診所和醫療機構數量的增加、該手術的保險覆蓋範圍以及推遲分娩和追求職業目標的趨勢激增,都積極支持了市場的成長。
The global artificial insemination market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. Increasing infertility rates, rapid lifestyle changes, and escalating prevalence of medical conditions represent some of the key factors driving the market.
Artificial insemination is a process of fertilization that involves the placement of sperm directly into the female reproductive system through medical procedures. It typically involves the use of either fresh or frozen sperm and can be done in a variety of ways, including intracervical, intrauterine, or intravaginal methods. The components of artificial insemination include semen collection, semen processing, and semen placement. Artificial insemination offers increased chances of conception, reduced risk of sexually transmitted infections (STIs), and the ability to use donor sperm in cases of male infertility. Additionally, as compared to in vitro fertilization (IVF), artificial insemination is minimally invasive (MI) and cost-effective. Currently, there are two primary types of the procedure, including homologous and heterologous. Homologous insemination involves using the male partner's sperm to fertilize the female partner's egg, while heterologous insemination involves using donor sperm to fertilize the female partner's egg.
The increasing infertility rates and the need for assisted reproductive technologies (ART) are some of the key factors boosting the market growth. The rapid lifestyle changes and escalating prevalence of medical conditions, such as polycystic ovary syndrome (PCOS) and endometriosis, have surged the demand for artificial insemination procedures, further accelerating the market growth. This is further supported by the growing acceptance and accessibility of artificial insemination in emerging economies. Moreover, various technological advancements, such as the development of improved techniques for sperm and egg selection, cryopreservation, and pre-implantation genetic testing, are propelling the market growth. Besides this, the availability of donor sperm and donor eggs, the rising popularity of same-sex marriage and LGBT parenting, and the improving healthcare infrastructure are factors expected to drive the market growth. Furthermore, the presence of favorable regulations, the growing awareness and education campaigns about infertility and artificial insemination, and the escalating demand for personalized and customized artificial insemination procedures are fueling the market growth. Other factors, such as the increasing number of clinics and healthcare facilities offering artificial insemination services, the availability of insurance coverage for the procedure, and the surging trend of delaying childbirth and pursuing career goals, are positively supporting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial insemination market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, source type and end use.
Intrauterine
Intracervical
Intravaginal
Intratubal
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the type. This includes intrauterine, intracervical, intravaginal, and intratubal. According to the report, the intrauterine segment dominates the market.
AIH-Husband
AID-Donor
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the source type. This includes AIH-husband and AID-donor.
Hospitals and Clinics
Fertility Centers
Others
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the end use. This includes hospitals and clinics, fertility centers, and others. According to the report, the fertility centers segment spearheads the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America artificial insemination market include the surging awareness regarding the advantages of artificial insemination, the rising consumer per capita expenditure, and burgeoning healthcare expenditure.
The report has also provided a comprehensive analysis of the competitive landscape in the global artificial insemination market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women's Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC, Vitrolife AB, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.